Compare Kaltura Inc (KLTR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 50.8× Kaltura Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KLTR | XBI | |
|---|---|---|
Market Cap | $199.08M | $10.11B |
Volume | 175,927 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $1.89 | $169.55 |
52-Week Low | $1.08 | $104.99 |
Typical Hold Time | 21 Days | 38 Days |
Enterprise Value | $211.29M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.305, down 1.88% with bearish technical signals. The company shows improving fundamentals with revenue stabilizing around $181M and narrowing losses, though still unprofitable. Recent positive developments include AI platform recognition and major streaming contracts, while valuation metrics remain elevated with P/S of 1.08 and EV/EBITDA of 271.59.
The outlook balances AI growth potential against persistent profitability challenges. Analyst consensus leans positive with 44% buy ratings, but high debt levels and negative cash flow present execution risks. The stock's direction hinges on AI monetization success and path to sustainable profitability.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
